Duration of Antibiotic Treatment in Community-acquired Pneumonia (ADAPT)
Community-acquired Pneumonia
About this trial
This is an interventional health services research trial for Community-acquired Pneumonia focused on measuring pneumonia, antibiotic treatment, duration, clinical stability, adherence
Eligibility Criteria
Inclusion Criteria: Patients >18 years hospitalized for community-acquired pneumonia with a new infiltrate on chest X-ray and/or computerized tomography. At least one compatible sign or symptom (fever, cough, expectoration, dyspnea, chest pain or crackles on auscultation) Correctly treated with ≥ 3 days of antibiotic Exclusion Criteria: Intensive care unit admission during the first 5 days since hospital admission Abscess or necrotizing pneumonia Empyema or pleural effusion requiring drainage tube Bronchiectasis Cystic fibrosis Active tuberculosis Postobstructive pneumonia Suspected bronchial aspiration SARS-CoV-2 infection Immunosuppression (congenital immunodeficiencies, HIV infection, solid organ transplantation, functional or anatomical asplenia, immunosuppressive treatment, active solid or haematological neoplasia [active treatment in the last 12 months], etc.) Hospital acquired pneumonia Concomitant extrapulmonary infection that requires antibiotic treatment for more than 5 days (eg myocarditis) Confirmed diagnosis alternative to pneumonia (eg, lung cancer)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
No Intervention
Other
Standard of care
Interventional
Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.
Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability